Skip to main content
. 2019 Apr 23;24(8):1128–1136. doi: 10.1634/theoncologist.2018-0563

Figure 1.

image

Overall survival of study population. Overall survival according to onset of immune‐related adverse events (A), neutrophil‐to‐lymphocyte ratio (B), and platelet‐to‐lymphocyte ratio (C).

Abbreviations: irAE, immune‐related adverse event; NLR, neutrophil‐to‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio.